New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...
REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of ...
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038. According to an article published in Becker's Hospital Review, a number of medical ...
As director of clinical trials, Sheth has served as principal investigator on more than 100 clinical trials, advancing ...
How equitably are glaucoma medications being dispensed across a universal health care system, and how have prescribing ...
Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics).
A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...
Vonaprument reduced the proportion of eyes with clinically meaningful vision loss, though not uniformly across doses. Through ...
Introducing Nicholas Riina, MS. Nicholas Riina, MS, had his eye on the prize early on, growing up in a family in which he was ...
An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...
Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 ...
Lexitas Pharma Services and Ocusun have announced enrollment of the first patient in a pilot study evaluating ZOC2017217, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results